Response Genetics Inc. announced execution of an exclusive commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University (OHSU) for a proprietary next generation sequencing panel for lung cancer. The panel provides full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots. The collaboration will leverage Response Genetics' national sales force and the Company expects to begin marketing the proprietary panel immediately.

With the addition of the OHSU next-generation sequencing panel for lung cancer, Response Genetics now offers oncologists and patients analyses of actionable genetic markers across six different tumor types and four different testing modalities. All of these tests will leverage Response Genetics' reporting that gives physicians easy to understand actionable information for patients.